RNS : FOR IMMEDIATE RELEASE |
26 OCTOBER 2016
|
ImmuPharma PLC
("ImmuPharma" or the "Company")
TR1 NOTIFICATION OF MAJOR INTEREST
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces that it has received a TR-1 by Lanstead Capital LP ("Lanstead"). Lanstead's holding in ImmuPharma is now confirmed at a total of 10,521,555 Ordinary Shares which equates to a current position in the Company of 8.4%.
Full disclosure of the TR1 is shown below:
-Ends-
For further information please contact:
|
|
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi
|
|
|
|||
1. Identity of the issuer or the underlying issuer |
Immupharma plc |
|||
2 Reason for the notification (please tick the appropriate box or boxes): |
||||
An acquisition or disposal of voting rights |
x |
|||
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached |
|
|||
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments |
|
|||
An event changing the breakdown of voting rights |
|
|||
Other (please specify): |
The placement by ImmuPharma PLC of 2,857,143 new ordinary shares |
x |
||
3. Full name of person(s) subject to the |
Lanstead Capital LP |
|||
4. Full name of shareholder(s) |
|
|||
5. Date of the transaction and date on |
21 October 2016 |
|||
6. Date on which issuer notified: |
25 October 2016 |
|||
7. Threshold(s) that is/are crossed or |
14%, 13%, 12%, 11%, 10%, 9% |
|||
8. Notified details: |
||||||||||||||||
A: Voting rights attached to shares viii, ix |
||||||||||||||||
Class/type of
|
Situation previous |
Resulting situation after the triggering transaction |
||||||||||||||
Number |
Number |
Number |
Number of voting |
% of voting rights x |
||||||||||||
Direct |
Direct xi |
Indirect xii |
Direct |
Indirect |
||||||||||||
GB0033711010 |
17,893,456 |
17,893,456 |
10,521,555 |
10,521,555 |
|
8.44% |
|
|||||||||
|
||||||||||||||||
|
||||||||||||||||
B: Qualifying Financial Instruments |
||||||||||||||||
Resulting situation after the triggering transaction |
||||||||||||||||
Type of financial |
Expiration |
Exercise/ |
Number of voting |
% of voting |
||||||||||||
N/A |
|
|
|
|
||||||||||||
|
||||||||||||||||
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi |
||||||||||||||||
Resulting situation after the triggering transaction |
||||||||||||||||
Type of financial |
Exercise price |
Expiration date xvii |
Exercise/ |
Number of voting rights instrument refers to
|
% of voting rights xix, xx
|
|||||||||||
N/A |
|
|
|
|
Nominal |
Delta |
||||||||||
|
|
|||||||||||||||
|
||||||||||||||||
Total (A+B+C) |
||||||||||||||||
Number of voting rights |
Percentage of voting rights |
|||||||||||||||
10,521,555 |
8.44% |
|||||||||||||||
9. Chain of controlled undertakings through which the voting rights and/or the |
||
N/A |
||
|
||
Proxy Voting: |
||
10. Name of the proxy holder: |
|
|
11. Number of voting rights proxy holder will cease to hold: |
|
|
12. Date on which proxy holder will cease to hold |
|
|
|
||
|
|
|
14. Contact name: |
Lisa De Vargas, Lanstead Partners Limited |
|
15. Contact telephone number: |
+1 (801) 895-3700 |
|